Nuveen LLC Invests $189,000 in Sutro Biopharma, Inc. $STRO

Key Points

• Nuveen LLC has invested approximately $189,000 in Sutro Biopharma, acquiring 290,897 shares, representing about 0.34% ownership of the company.
• Sutro Biopharma’s stock price has seen fluctuations, trading up 3.9% recently, with a 12-month low of $0.52 and a high of $4.80.
• Analysts have mixed views on Sutro Biopharma, with price targets ranging from $0.80 to $4.47, and ratings varying from "underperform" to "buy."

Nuveen LLC acquired a new position in Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 290,897 shares of the company's stock, valued at approximately $189,000. Nuveen LLC owned approximately 0.34% of Sutro Biopharma at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Suvretta Capital Management LLC increased its stake in shares of Sutro Biopharma by 3.8% in the 4th quarter. Suvretta Capital Management LLC now owns 7,462,495 shares of the company's stock worth $13,731,000 after purchasing an additional 275,000 shares in the last quarter. Vestal Point Capital LP purchased a new stake in shares of Sutro Biopharma in the 4th quarter worth $4,729,000. Parkman Healthcare Partners LLC increased its stake in shares of Sutro Biopharma by 0.7% in the 4th quarter. Parkman Healthcare Partners LLC now owns 1,727,925 shares of the company's stock worth $3,179,000 after purchasing an additional 11,793 shares in the last quarter. Nuveen Asset Management LLC increased its stake in shares of Sutro Biopharma by 10.3% in the 4th quarter. Nuveen Asset Management LLC now owns 1,323,777 shares of the company's stock worth $2,436,000 after purchasing an additional 124,154 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of Sutro Biopharma by 15.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,136,457 shares of the company's stock worth $2,091,000 after purchasing an additional 156,139 shares in the last quarter. 96.99% of the stock is currently owned by hedge funds and other institutional investors.

Sutro Biopharma Trading Up 3.9%

Shares of NASDAQ:STRO opened at $1.06 on Friday. Sutro Biopharma, Inc. has a 12 month low of $0.52 and a 12 month high of $4.80. The company has a 50-day moving average price of $0.83 and a 200 day moving average price of $0.89. The company has a market cap of $89.86 million, a price-to-earnings ratio of -0.42 and a beta of 1.57.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.39) by $0.25. The firm had revenue of $63.74 million during the quarter, compared to the consensus estimate of $14.55 million. Sutro Biopharma had a negative net margin of 201.32% and a negative return on equity of 852.70%. As a group, equities analysts forecast that Sutro Biopharma, Inc. will post -2.92 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on STRO shares. Bank of America reduced their price objective on Sutro Biopharma from $1.00 to $0.80 and set an "underperform" rating for the company in a research note on Monday, May 19th. Piper Sandler upgraded Sutro Biopharma from a "neutral" rating to an "overweight" rating and set a $2.00 price target for the company in a research note on Monday, June 16th. Wall Street Zen lowered Sutro Biopharma from a "hold" rating to a "sell" rating in a research note on Friday, August 22nd. Finally, Wells Fargo & Company cut their price target on Sutro Biopharma from $4.00 to $3.00 and set an "equal weight" rating for the company in a research note on Tuesday, August 12th. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $4.47.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.